IPP Bureau
Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
By IPP Bureau - February 09, 2026
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
By IPP Bureau - February 09, 2026
HCG clinicians contributing to one of the largest bodies of oncology research from India
Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
By IPP Bureau - February 09, 2026
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
By IPP Bureau - February 09, 2026
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
By IPP Bureau - February 09, 2026
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
By IPP Bureau - February 09, 2026
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Wanbury reports explosive Q3 profit surge, signals strong growth ahead
By IPP Bureau - February 09, 2026
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
KIMS Hospitals crosses Rs. 1,000 crore quarterly revenue milestone
By IPP Bureau - February 09, 2026
MHRA warns of extremely rare vision risk linked to semaglutide
By IPP Bureau - February 09, 2026
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
By IPP Bureau - February 07, 2026
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
By IPP Bureau - February 07, 2026
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
By IPP Bureau - February 07, 2026
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
By IPP Bureau - February 07, 2026
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
By IPP Bureau - February 07, 2026
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
By IPP Bureau - February 07, 2026
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
